Stockreport

Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound TAMPA, Fla.--(BUSINESS WIRE)-- [Read more]